FDA approves sublingual apomorphine in off periods - UDIC Unitat D'Investigació Clínica

The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s disease with motor fluctuations. We have led the clinical trial in Spain with this drug. Our patients are continuing to use it during the open label extension.

US authorizes an intranasal levodopa.

8 de April de 2020

An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija….

Posted in: Parkinson

Levodopa infusion pump

2 de April de 2020

Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations….

Posted in: Parkinson

Activation of phase I trial in Progressive Supranuclear Palsy

11 de March de 2020

Our Unit has achieved to be activated in this outstanding project and so serious pathology….

Posted in: Parkinson

We continue a phase I clinical trial in Parkinson

5 de March de 2020

We appreciate the great effort made by our patients to contribute to the development of…

Posted in: Parkinson

An amazing Phase I trial in Parkinson

9 de January de 2020

We have been activated in this trial that evaluates the safety of an innovative compound…

Posted in: Parkinson

Our clinical trials unit remains in prominent position

9 de January de 2020

We have reached the first position, in December 2019, in the international inclusion of patients…

Posted in: Alzeimer, News, Parkinson

Positive result of the GRIFOLS trial in Alzheimer’s

12 de December de 2019

Grifols has reported to the press the positive result of the AMBAR trial in patients…

Posted in: Alzeimer, Alzeimer, Uncategorised

Tavapadon (Cerevel): A very different dopamine agonist

29 de November de 2019

The UDIC has been selected to initiate a line of several clinical trials with this…

Posted in: Parkinson

Related Stories